We are excited to continue our Molecule of the Month series. Stay tuned! We're kicking off January with MIBG Hemisulfate:
Iodine-123 metaiodobenzylguanidine (I-123 mIBG) is a radiopharmaceutical widely used in nuclear medicine for diagnosis in both cardiology and oncology [1]. Iodine-131 metaiodobenzylguanidine (I-131 mIBG) is mainly used for radiotherapy of neuroblastoma [2]. Both radiopharmaceuticals have been used intensively for decades. The precursor MIBG Hemisulfate (GMP) is available from ABX as API and ABX has a US DMF.
[1] Ming-Cheng Chang et al. Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review. Pharmaceuticals 2024, 17, 1563. [2] Atia Samim et al. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma. EJC Paediatric Oncology 2024, 3, 100159.
Learn more about this compound and send us your quote request:
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of about 400 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.
